< Click or tap for more information

Aspen has a strong presence in both emerging and developed countries with more than 60 established business operations in approximately 50 countries. The Group supplies medicines and products to more than 150 countries.

International business

R18.6 billion*

Contribution to gross revenue

* Comparable revenue excludes the contribution from divestments and includes the results of Aspen’s Venezuelan business translated at the DICOM (previously SIMADI) rate of VEF628,34 per USD for the prior reporting period. 

Key territories and/or countries supplied to in this region 

• Argentina • Brazil • Canada • Caricam • Chile • CIS
• Colombia • Ecuador • Europe • Mexico • MENA
•  Panama • Peru • USA 

1Toluca, Mexico
2Mexico City, Mexico
3Vallejo, Mexico
4San José, Costa Rica
5Panama City, Panama
6Bogotá, Colombia
7Quito, Ecuador
8Lima, Peru
9Santiago, Chile
10Buenos Aires, Argentina
11Rio de Janeiro, Brazil
12Vitória, Brazil
13Sioux City, IL USA
14Des Plaines, IA USA
15Bridgewater, NJ USA
16Montreal, Canada
17Dublin, Ireland
18London, United Kingdom
19Bad Oldesloe, Germany
20Munich, Germany
21Oss, the Netherlands
22Amsterdam, the Netherlands
23Brussels, Belgium
24Notre Dame de Bondeville, France
25Paris, France
26Baar, Switzerland
27Verona, Italy
28Prague, Czech Republic
29Ljubljana, Slovenia
30Baloži, Latvia
31Warsaw, Poland
32Bratislava, Slovakia
33Budapest, Hungary
34Belgrade, Serbia
35Athens, Greece
36Moscow, Russia
37Kiev, Ukraine
38Bucharest, Romania
39Sofia, Bulgaria
40Hyderabad, India
41Dubai, United Arab Emirates
42Grand Bay, Mauritius

Key:

Group headquarters
Combined sales, marketing, distribution and manufacturing centres
Sales, marketing and distribution centres
Marketing centres
Branch/representative offices
Manufacturing sites

Aspen’s International business comprises operating subsidiaries in Europe CIS, Latin America, Middle East and North Africa (“MENA”), Canada as well as Mauritian-based AGI, the international commercial business and intellectual property holding company which is also a primary Group trading operation and supply chain hub. Globally branded pharmaceutical products are distributed into multiple territories as well as local brands into selected regions. The API site at Oss, supported by its satellite operation at Sioux City, supplies APIs worldwide. The Notre Dame de Bondeville site primarily services Group supply needs and the Bad Oldesloe site is also an important producer for the Group.

Asia Pacific business

R7,4 billion* 

Contribution to gross revenue

* Comparable revenue excludes the contribution from divestments and includes the results of Aspen’s Venezuelan business translated at the DICOM (previously SIMADI) rate of VEF628,34 per USD for the prior reporting period. 

Key territories and/or countries supplied to in this region 

• Australia • China • Hong  Kong • Indonesia • Japan
• Korea • Malaysia • New Zealand • Philippines
• Singapore • Taiwan • Thailand • Vietnam 

43Kuala Lumpur, Malaysia
44Quarry Bay, Hong Kong
45Guangzhou, China
46Tokyo, Japan
47Taipei, Taiwan
48Manila, the Philippines
49Sydney, Australia
50Melbourne, Australia
51 Auckland, New Zealand

Key

Group headquarters
Combined sales, marketing, distribution and manufacturing centres
Sales, marketing and distribution centres
Marketing centres
Branch/representative offices
Manufacturing sites

Australia, New Zealand, the Philippines, Malaysia, Taiwan and Japan. Efforts are underway to establish an operation in China, following Aspen’s recent acquisition of anaesthetic and thrombosis products from AstraZeneca and GSK in this country. These operations supply a diversified portfolio of branded prescription, generic, OTC, consumer and infant nutritional products into Australia and New Zealand and the majority of countries in Asia. Certain tablets, liquids and semi-solids are produced at the Group’s manufacturing site in Melbourne, while other products for customers of this business are sourced from Aspen’s global manufacturing sites and accredited third-party manufacturers.

South African business

R8,1 billion*

Contribution to gross revenue

* Comparable revenue excludes the contribution from divestments and includes the results of Aspen’s Venezuelan business translated at the DICOM (previously SIMADI) rate of VEF628,34 per USD for the prior reporting period. 

Key territories and/or countries supplied to in this region

• Botswana • Lesotho • Namibia
• South Africa • Swaziland

52Durban, South Africa
53Cape Town, South Africa
54Johannesburg, South Africa
55Port Elizabeth, South Africa
56East London, South Africa

Key

Group headquarters
Combined sales, marketing, distribution and manufacturing centres
Sales, marketing and distribution centres
Marketing centres
Branch/representative offices
Manufacturing sites

The South African business provides a diverse basket of branded, generic, OTC, consumer health and infant nutritional products which are supplied to pharmacies, retail pharmacy chains, hospitals, clinics, prescribing specialists, dispensing general practitioners, managed healthcare funders and retail stores across the private and public sectors in South Africa.

Sub-Saharan Africa business

R3,3 billion*

Contribution to gross revenue

* Comparable revenue excludes the contribution from divestments and includes the results of Aspen’s Venezuelan business translated at the DICOM (previously SIMADI) rate of VEF628,34 per USD for the prior reporting period. 

Key territories and/or countries supplied to in this region 

• Angola • Botswana • Ethiopia • Ghana • Ivory Coast
• Kenya • Mauritius • Namibia • Nigeria
• Tanzania • Uganda • Zambia • Zimbabwe

57Accra, Ghana
58Lagos, Nigeria
59Kampala, Uganda
60Nairobi, Kenya
61Dar es Salaam, Tanzania

Key

Group headquarters
Combined sales, marketing, distribution and manufacturing centres
Sales, marketing and distribution centres
Marketing centres
Branch/representative offices
Manufacturing sites

Aspen’s presence in SSA is through its wholly owned subsidiaries, Shelys (Tanzania), Beta Healthcare International (Kenya), Beta Healthcare (Uganda) and Aspen Nigeria. Aspen also has a 65% shareholding in Kama (Ghana) and exports products from South Africa into selected territories. While it was agreed to terminate the SSA Collaboration between Aspen and GSK after the 2016 year end close, the SSA Collaboration was an important contributor to the revenue of this region for the 2016 financial year. Aspen uses its own sales representation and distribution infrastructure across the region to supply a range of high quality pharmaceutical products. Aspen has its own operations in Nigeria, Ghana, Kenya, Tanzania, and Uganda, with the rest of the region being serviced through long-standing relationships with local distributors supported by sales representatives. Aspen supplies a range of branded, generic, OTC, consumer health and infant nutritional products into SSA.